 |
|
|
| |
Trial design, enrollment status, demographics, and pharmacokinetic (PK) data from a blinded interim analysis from a phase 2a trial of islatravir once monthly (QM) for HIV pre-exposure prophylaxis (PrEP)
|
| |
| |
HIVR4P 2021 (Virtual event); 27-28 January & 3-4 February 2021
Reported by Jules Levin
S. Hillier,1L.G. Bekker,2S. Badal-Faesen,3C.W. Hendrix,4S.A. Riddler,5S. Rasmussen,6
H. Schwartz,7G. Nair,2J.H. Lombaard,8Y. Caraco,9A. Peer,10M. Patel,11B. Evans,11B. Homony,11V. Teal,11P. Hwang,11M. Robertson,11R. Plank11
1Magee-Womens Research Institute & Foundation, Pittsburgh, PA, USA; 2Desmond Tutu HIV Centre, Cape Town, South Africa; 3University of the Witwatersrand, Johannesburg, South Africa; 4Johns Hopkins Hospital, Baltimore, MD, USA; 5University of Pittsburgh, Pittsburgh, PA, USA; 6Celerion, Lincoln, NE, USA; 7Research Centers of America, Hollywood, CA, USA; 8Josha Research, Bloemfontein, South Africa; 9Hadassah Medical Center, Jerusalem, Israel; 10Rambam Health Care Campus, Haifa, Israel; 11Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
